CureVac N.V. (CVAC)
NASDAQ: CVAC · IEX Real-Time Price · USD
3.130
+0.360 (13.00%)
At close: May 3, 2024, 4:00 PM
3.140
+0.010 (0.32%)
After-hours: May 3, 2024, 7:23 PM EDT
CureVac Revenue
In the year 2023, CureVac had annual revenue of $59.73M, a decrease of -16.72%. Revenue in the quarter ending December 31, 2023 was $25.07M with 101.64% year-over-year growth.
Revenue (ttm)
$59.73M
Revenue Growth
-16.72%
P/S Ratio
11.73
Revenue / Employee
$66,074
Employees
904
Market Cap
700.75M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 59.73M | -11.99M | -16.72% |
Dec 31, 2022 | 71.72M | -45.31M | -38.72% |
Dec 31, 2021 | 117.03M | 57.44M | 96.37% |
Dec 31, 2020 | 59.60M | 40.03M | 204.56% |
Dec 31, 2019 | 19.57M | 4.77M | 32.27% |
Dec 31, 2018 | 14.79M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Novavax | 983.71M |
Phibro Animal Health | 982.01M |
Pharming Group | 272.57M |
Treace Medical Concepts | 187.12M |
AnaptysBio | 17.16M |
Autolus Therapeutics | 1.70M |
CVAC News
- 9 days ago - CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update - Accesswire
- 9 days ago - CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK - Accesswire
- 9 days ago - CureVac Appoints Thaminda Ramanayake as New Chief Business Officer - Accesswire
- 15 days ago - CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024 - Accesswire
- 17 days ago - CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines - Accesswire
- 4 weeks ago - CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK - Accesswire
- 4 months ago - CureVac stock gains as COVID vaccine candidates show promise - Market Watch
- 4 months ago - CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform - Accesswire